Industry News

8 October 2026

Nova Biomedical Issues Global Correction for StatStrip Glucose Meter Over Wrong-Patient Result Risk

Nova Biomedical has initiated a global medical device correction for its StatStrip Glucose Hospital Meter System after identifying a software issue that could cause a glucose test result to be associated with the wrong patient's medical record. The U.S. Food and Drug Administration (FDA) published the company's safety announcement on October 6, 2026.

7 October 2026

Glenmark Launches Adapalene 0.1% OTC Gel in New Pump Packs in the U.S

Glenmark Therapeutics Inc., USA, has announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump-pack presentations in the United States. The new pump-pack format is designed to provide consumers with a more convenient and easy-to-use dispensing option.

7 October 2026

Shionogi to Acquire IntraBio for 2 Billion USD, Expanding Rare Disease Drug Portfolio

Japanese pharmaceutical company Shionogi & Co., Ltd. has announced a planned acquisition of IntraBio Inc., a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare neurodegenerative and genetic neurological diseases.

7 October 2026

Bayer Plans 2.2 Billion USD Ohio Manufacturing Campus, Set to Create 600 Pharma Jobs

Bayer has announced plans to invest 2.2 billion USD in a new pharmaceutical manufacturing site in New Albany, Ohio, United States, as the company expands its pharmaceutical manufacturing capabilities and strengthens its presence in the U.S. market.

6 October 2026

AstraZeneca Completes $2 Billion Investment in Summit Therapeutics to Advance Ivonescimab-ADC Cancer Strategy

AstraZeneca has completed its 2 billion USD equity investment in Summit Therapeutics, strengthening a strategic partnership focused on advancing ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody-drug conjugates (ADCs) across multiple cancer types.

6 October 2026

Zydus, MSN Launch First Generic Riociguat in U.S., Challenging Bayer’s Adempas

Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched Riociguat Tablets in the United States, becoming the first companies to market a generic version of Bayer’s Adempas® (riociguat) in the country.

5 October 2026

Biodeal Pharma Expands Injectable Manufacturing with Biological E Facility Acquisition

Biodeal Pharmaceuticals Limited has strengthened its sterile injectable manufacturing and CDMO capabilities by acquiring a manufacturing facility of Biological E. Limited at Paonta Sahib in Himachal Pradesh.

The acquisition is part of Biodeal’s broader strategy to expand its pharmaceutical contract development and manufacturing capabilities and build a stronger presence in regulated international markets. The acquired manufacturing facility spans approximately 14 acres and has an annual production capacity of around 135 million units.

5 October 2026

CERVAVAC Enters WHO-Qualified Vaccine List, Opening Door to Global HPV Vaccine Procurement

Indias indigenous quadrivalent Human Papillomavirus (HPV) vaccine CERVAVAC, manufactured by Serum Institute of India Pvt. Ltd., has received WHO prequalification, marking a significant milestone for India’s HPV vaccine programme and its potential global reach.

5 October 2026

Sun Pharma Presents Two-Year LEQSELVI Data at EADV 2026, Showing Sustained Hair Regrowth in Severe Alopecia Areata

Sun Pharmaceutical Industries Limited has announced new long-term data for LEQSELVI® (deuruxolitinib) in adults with severe alopecia areata at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The company said LEQSELVI was featured in seven presentations, including data from a European open-label extension study evaluating treatment for up to two years.

1 October 2026

MSD’s Tulisokibart Hits Key Endpoints in Phase 2b HS Study

MSD announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS).

Nova Biomedical Issues Global Correction for StatStrip Glucose Meter Over Wrong-Patient Result Risk

RECOMMENDED POSTS

Subscribe with us

Jobs by Category